FDA approves ARS' neffy 1mg for paediatric anaphylaxis [Yahoo! Finance]
ARS Pharmaceuticals, Inc. (SPRY)
Company Research
Source: Yahoo! Finance
reactions including anaphylaxis in paediatric patients aged four years and above weighing between 15kg and 30kg. Neffy's needle-free administration allows for an instantaneous epinephrine dose through a nasal spray without the need for a nasal hold period. The approval is supported by data from clinical trials, including pharmacodynamic and pharmacokinetic responses in both paediatric subjects and adults that were consistent with those of epinephrine injection products. ARS Pharmaceuticals CEO, president and co-founder Richard Lowenthal stated: “Today's FDA approval of neffy 1mg marks a major milestone towards our efforts to transform the management of severe allergic reactions. “With nearly four out of 10 US epinephrine prescriptions written for children under the age of 18 — and nearly a third of those for children weighing 15 to 30 kilograms — we believe neffy 1mg will improve access to a needle-free option for the treatment of severe allergies and reduce hesitation in trea
Show less
Read more
Impact Snapshot
Event Time:
SPRY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SPRY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SPRY alerts
High impacting ARS Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
SPRY
News
- neffy® (epinephrine nasal spray) Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions (anaphylaxis) [Yahoo! Finance]Yahoo! Finance
- neffy® (epinephrine nasal spray) Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions (anaphylaxis)GlobeNewswire
- How Recent Developments Are Shaping the Story for ARS Pharmaceuticals According to Analysts [Yahoo! Finance]Yahoo! Finance
- ARS Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- ARS Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare ConferenceGlobeNewswire
SPRY
Earnings
- 11/10/25 - Miss
SPRY
Sec Filings
- 11/14/25 - Form 4
- 11/14/25 - Form 4
- 11/14/25 - Form 4
- SPRY's page on the SEC website